The dopamine hypothesis of schizophrenia revisited.
D014150:Antipsychotic Agents / Q000627:therapeutic use; D002540:Cerebral Cortex / Q000503:physiopathology; D003342:Corpus Striatum / Q000503:physiopathology; D004298:Dopamine / Q000502:physiology*; D004299:Dopamine beta-Hydroxylase / Q000134:cerebrospinal fluid; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D008032:Limbic System / Q000503:physiopathology; D008636:Mesencephalon / Q000503:physiopathology; D009434:Neural Pathways / Q000503:physiopathology; D011388:Prolactin / Q000097:blood; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology*; D012565:Schizophrenic Psychology; D012919:Social Behavior; D013378:Substantia Nigra / Q000503:physiopathology; D005680:gamma-Aminobutyric Acid / Q000134:cerebrospinal fluid
D014150:Antipsychotic Agents; D011954:Receptors, Dopamine; D005680:gamma-Aminobutyric Acid; D011388:Prolactin; D004299:Dopamine beta-Hydroxylase; D004298:Dopamine; D006719:Homovanillic Acid